Shanghai Medicilon Inc. — Investor Relations & Filings
Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 美迪西：2021年年度报告（修订版） | 2022-04-24 | Chinese | |
| 美迪西：独立董事关于第三届董事会第五次会议相关事项的独立意见 | 2022-04-24 | Chinese | |
| 美迪西：第三届监事会第五次会议决议公告 | 2022-04-24 | Chinese | |
| 美迪西：2021年度内部控制评价报告 | 2022-04-06 | Chinese | |
| 美迪西：2021年度独立董事述职报告 | 2022-04-06 | Chinese | |
| 美迪西：立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司2021年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2022-04-06 | Chinese |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
15 filings
| |||||
| 38880722 | 美迪西：2021年年度报告（修订版） | 2022-04-24 | Chinese | ||
| 38880632 | 美迪西：独立董事关于第三届董事会第五次会议相关事项的独立意见 | 2022-04-24 | Chinese | ||
| 38880593 | 美迪西：第三届监事会第五次会议决议公告 | 2022-04-24 | Chinese | ||
| 38880585 | 美迪西：2021年度内部控制评价报告 | 2022-04-06 | Chinese | ||
| 38880555 | 美迪西：2021年度独立董事述职报告 | 2022-04-06 | Chinese | ||
| 38880523 | 美迪西：立信会计师事务所（特殊普通合伙）关于上海美迪西生物医药股份有限公司2021年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2022-04-06 | Chinese | ||
| 38880461 | 美迪西：独立董事关于第三届董事会第四次会议相关事项的事前认可意见 | 2022-04-06 | Chinese | ||
| 38880421 | 美迪西：关于聘任公司2022年度审计机构及内控审计机构的公告 | 2022-04-06 | Chinese | ||
| 38880390 | 美迪西：独立董事关于第三届董事会第四次会议相关事项的独立意见 | 2022-04-06 | Chinese | ||
| 38880367 | 美迪西：董事会审计委员会2021年度履职情况报告 | 2022-04-06 | Chinese | ||
| 38880345 | 美迪西：截至2021年12月31日止前次募集资金使用情况报告的鉴证报告 | 2022-04-06 | Chinese | ||
| 38880255 | 美迪西：关于使用部分超募资金永久补充流动资金的公告 | 2022-04-06 | Chinese | ||
| 38880244 | 美迪西：关于使用自有闲置资金进行现金管理的公告 | 2022-04-06 | Chinese | ||
| 38880235 | 广发证券股份有限公司关于上海美迪西生物医药股份有限公司2021年度募集资金存放与使用情况的核查意见 | 2022-04-06 | Chinese | ||
| 38880224 | 美迪西：独立董事关于公司2021年的对外担保情况的专项说明 | 2022-04-06 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Shanghai Medicilon Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58233/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58233 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58233 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58233 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58233}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Shanghai Medicilon Inc. (id: 58233)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.